Dali Pharmaceuticalco.,Ltd

Shanghai Stock Exchange 603963.SS

Dali Pharmaceuticalco.,Ltd Price to Sales Ratio (P/S) on January 14, 2025: 4.48

Dali Pharmaceuticalco.,Ltd Price to Sales Ratio (P/S) is 4.48 on January 14, 2025, a -84.39% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Dali Pharmaceuticalco.,Ltd 52-week high Price to Sales Ratio (P/S) is 39.63 on March 21, 2024, which is 783.78% above the current Price to Sales Ratio (P/S).
Dali Pharmaceuticalco.,Ltd 52-week low Price to Sales Ratio (P/S) is 4.48 on January 14, 2025, which is 0.00% below the current Price to Sales Ratio (P/S).
Dali Pharmaceuticalco.,Ltd average Price to Sales Ratio (P/S) for the last 52 weeks is 12.27.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shanghai Stock Exchange: 603963.SS

Dali Pharmaceuticalco.,Ltd

CEO	Mr. Jun Xiang Yang
IPO Date	Sept. 22, 2017
Location	China
Headquarters	No. 118, West Huancheng Road
Employees	272
Sector	Health Care
Industries Pharmaceuticals

Description

Dali Pharmaceuticalco.,Ltd researches, develops, produces, and sells pharmaceutical products in China. It develops Chinese and Western medicine injection products of 20 varieties with 44 specifications of the injection drug approval number. The company's products include xingnaojing, shenmai, and astragalus injections, as well as leucocin A and citicoline injections. It also has 31 patents, including 11 invention patents, 16 utility models, and 3 design patents. The company was founded in 1996 and is headquartered in Dali, China.

Key trends

Past 5 years